A Holliston-based clinical research organization will be providing services to a Texas biopharmaceutical company.
Veristat of Holliston said it will provide a series of clinical support services to Molecular Templates, of Georgetown, Texas. The services will include clinical monitoring, safety management, data management, data monitoring committee services, statistics and medical writing support for Molecular’s lead compound. The compound, MT-3724, is an immunotoxin that helps patients with relapsed non-Hodgkin’s lymphoma. The drug will enter clinical trials during the current quarter, Veristat said.
The drug recently received approval from the U.S. Food and Drug Administration as an “investigational new drug,” enabling Molecular to launch clinical trials.
